Gastroesophageal Junction Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GST012 MIFTS: 36	Gastroesophageal Junction Adenocarcinoma Categories: Cancer diseases, Gastrointestinal diseases, Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Gastroesophageal Junction Adenocarcinoma

MalaCards integrated aliases for Gastroesophageal Junction Adenocarcinoma:

Name: Gastroesophageal Junction Adenocarcinoma ¹² ¹⁵

Adenocarcinoma of the Gastroesophageal Junction ⁷³

Adenocarcinoma of Cardioesophageal Junction ¹²

Adenocarcinoma of Gastroesophageal Junction ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases Cardiovascular diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:4944

NCIt ⁵⁰ C9296

UMLS ⁷³ C1332166

Sources

Summaries for Gastroesophageal Junction Adenocarcinoma

MalaCards based summary : Gastroesophageal Junction Adenocarcinoma, also known as adenocarcinoma of the gastroesophageal junction, is related to adenocarcinoma and esophagitis, and has symptoms including abdominal pain An important gene associated with Gastroesophageal Junction Adenocarcinoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are MAPK Pathway and Adherens junction. The drugs Herceptin and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and prostate, and related phenotype is cardiovascular system.

Sources

Related Diseases for Gastroesophageal Junction Adenocarcinoma

Diseases related to Gastroesophageal Junction Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

#	Related Disease	Score	Top Affiliating Genes
1	adenocarcinoma	10.8
2	esophagitis	10.3
3	helicobacter pylori infection	10.0
4	meningitis	9.8
5	lymphomatous meningitis	9.8
6	gastrointestinal system cancer	9.5	ERBB2 SNAI1
7	keratoconjunctivitis sicca	9.4	ERBB2 IL1B
8	pancreas adenocarcinoma	9.3	ERBB2 SNAI1
9	cercarial dermatitis	9.3	IL1B SNAI1

Graphical network of the top 20 diseases related to Gastroesophageal Junction Adenocarcinoma:

Sources

Symptoms & Phenotypes for Gastroesophageal Junction Adenocarcinoma

UMLS symptoms related to Gastroesophageal Junction Adenocarcinoma:

abdominal pain

MGI Mouse Phenotypes related to Gastroesophageal Junction Adenocarcinoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	8.92	ERBB2 GUCY2C IL1B SNAI1

Sources

Drugs & Therapeutics for Gastroesophageal Junction Adenocarcinoma

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Herceptin ¹⁸ ⁴⁹	TRASTUZUMAB	Genentech	October 1998
FDA Label: Herceptin Disease/s that Drug Treats:Breast cancer/gastric cancer Indications and Usage: ¹⁸ Herceptin is a HER2/neu receptor antagonist indicated for: the treatment of HER2 overexpressing breast cancer (1.1, 1.2). the treatment of HER2-overexpressing metastatic gastric orgastroesophageal junction adenocarcinoma (1.3) DrugBank Targets: ¹⁶ 1. Receptor tyrosine-protein kinase erbB-2;2. Epidermal growth factor receptor;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Complement C1s subcomponent;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c;12. Low affinity immunoglobulin gamma Fc region receptor III-B;13. Low affinity immunoglobulin gamma Fc region receptor III-A Mechanism of Action: ¹⁸ Target: human epidermal growth factor receptor 2 protein (HER2) Action: binds with strong affinity for immune response FDA: The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro, Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.

Drugs for Gastroesophageal Junction Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Capecitabine

Approved, Investigational

Phase 3,Phase 2,Phase 1

154361-50-9

60953

Cisplatin

Approved

Phase 3,Phase 2,Phase 1,Early Phase 1

15663-27-1

84093 441203 2767

Oxaliplatin

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1

61825-94-3

5310940 9887054 43805 6857599

Trastuzumab

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

180288-69-1

9903

Docetaxel

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1

114977-28-5

148124

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1,Early Phase 1

51-21-8

3385

Bevacizumab

Approved, Investigational

Phase 2, Phase 3

216974-75-3

Levoleucovorin

Approved, Investigational

Phase 3,Phase 1,Phase 2

68538-85-2

Irinotecan

Approved, Investigational

Phase 3,Phase 2,Phase 1

97682-44-5, 100286-90-6

60838

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1

33069-62-4

36314

Cetuximab

Approved

Phase 3,Phase 2

205923-56-4

56842117 2333

Gefitinib

Approved, Investigational

Phase 3

184475-35-2

123631

Ramucirumab

Approved, Investigational

Phase 3,Phase 2,Phase 1

947687-13-0

Epirubicin

Approved

Phase 3,Phase 2,Early Phase 1

56420-45-2

41867

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 498142 38904

Pembrolizumab

Approved

Phase 3,Phase 2,Phase 1

1374853-91-4

Adenosine

Approved, Investigational

Phase 2, Phase 3

58-61-7

60961

leucovorin

Approved, Nutraceutical

Phase 3,Phase 1,Phase 2

58-05-9

143 6006

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 1,Phase 2

59-30-3

6037

Lapatinib

Approved March 2007, Investigational

Phase 2, Phase 3,Phase 3,Phase 1

231277-92-2, 388082-78-8

208908 9941095

s 1 (combination)

Phase 3,Phase 2,Phase 1

Mitogens

Phase 3,Phase 2,Phase 1

Angiogenesis Inhibitors

Phase 2, Phase 3

Angiogenesis Modulating Agents

Phase 2, Phase 3

Antibodies

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1,Early Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1,Early Phase 1

Antimitotic Agents

Phase 2, Phase 3,Phase 3,Phase 1

Analgesics

Phase 3,Phase 1

topoisomerase I inhibitors

Phase 3,Phase 2,Phase 1

Central Nervous System Stimulants

Phase 3

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1,Early Phase 1

Opiate Alkaloids

Phase 3

Endothelial Growth Factors

Phase 3,Phase 1

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1,Early Phase 1

Antiemetics

Phase 3

Protein Kinase Inhibitors

Phase 3,Phase 2,Phase 1

Appetite Stimulants

Phase 3

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

taxane

Phase 2, Phase 3

Alkylating Agents

Phase 3

Ado-trastuzumab emtansine

Phase 2, Phase 3,Phase 1

Mitomycins

Phase 3

Nucleic Acid Synthesis Inhibitors

Phase 3

Pharmaceutical Solutions

Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 166)

#	Name	Status	NCT ID	Phase	Drugs
1	Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer	Unknown status	NCT01786278	Phase 2, Phase 3
2	A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer	Unknown status	NCT02409199	Phase 2, Phase 3	Docetaxel;apatinib
3	A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer	Completed	NCT02178956	Phase 3	BBI608;Paclitaxel
4	Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma	Completed	NCT00917384	Phase 3	Placebo
5	Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach	Completed	NCT01640782	Phase 3	Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
6	Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy	Completed	NCT01243398	Phase 3
7	Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer	Completed	NCT00678535	Phase 3	Cetuximab;Capecitabine;Cisplatin
8	A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma	Completed	NCT01170663	Phase 3	Placebo;Paclitaxel
9	Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer	Completed	NCT00978549	Phase 3	docetaxel;steroid therapy
10	Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction	Recruiting	NCT01523015	Phase 2, Phase 3
11	Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction	Recruiting	NCT01962246	Phase 2, Phase 3	Oxaliplatin; Capecitabine
12	A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer	Recruiting	NCT02898077	Phase 3	Ramucirumab;Paclitaxel;Placebo
13	S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients	Recruiting	NCT01824459	Phase 3	S-1;Oxaliplatin;Cisplatin
14	Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma	Recruiting	NCT02193594	Phase 2, Phase 3	Adjuvant chemotherapy
15	Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients	Recruiting	NCT02381847	Phase 3
16	Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer	Recruiting	NCT01917552	Phase 3	capecitabine
17	Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis	Recruiting	NCT02158988	Phase 3
18	Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus	Recruiting	NCT02509286	Phase 3	5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
19	Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer	Recruiting	NCT00450203	Phase 2, Phase 3	capecitabine;cisplatin;Epirubicin;Lapatinib
20	A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)	Active, not recruiting	NCT02370498	Phase 3	paclitaxel
21	Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-	Active, not recruiting	NCT03019588	Phase 3	Paclitaxel
22	Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)	Active, not recruiting	NCT02625623	Phase 3	Avelumab;Irinotecan;Paclitaxel
23	Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Active, not recruiting	NCT02545504	Phase 3	Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
24	A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer	Active, not recruiting	NCT02314117	Phase 3	Ramucirumab;Capecitabine;Cisplatin;Placebo;Fluorouracil
25	Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)	Active, not recruiting	NCT02494583	Phase 3	cisplatin;5-FU;capecitabine
26	LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib	Active, not recruiting	NCT00680901	Phase 3	Lapatinib;Placebo;Capecitabine;Oxaliplatin
27	Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery	Active, not recruiting	NCT01107639	Phase 3	cisplatin;docetaxel
28	Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)	Active, not recruiting	NCT02564263	Phase 3	paclitaxel;docetaxel;irinotecan
29	Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer	Active, not recruiting	NCT01196390	Phase 3	Carboplatin;Paclitaxel
30	A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer	Terminated	NCT02137343	Phase 3	Rilotumumab;Placebo;Cisplatin;Capecitabine
31	A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer	Terminated	NCT01450696	Phase 3	Capecitabine;Cisplatin;Herceptin
32	First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma	Terminated	NCT01697072	Phase 3	Rilotumumab;Epirubicin;Cisplatin;Capecitabine
33	A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer	Terminated	NCT01641939	Phase 2, Phase 3	Taxane;trastuzumab emtansine;trastuzumab emtansine
34	Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Unknown status	NCT01379807	Phase 2	panitumumab + docetaxel + cisplatino
35	Phase II Study of Neoadjuvant Taxotere, Cisplatin, and 5-Fluorouracil in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma	Unknown status	NCT00763646	Phase 2	Taxotere, Cisplatin, and 5-FU
36	Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer	Unknown status	NCT02525237	Phase 2	Apatinib;S-1
37	Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer	Unknown status	NCT01359397	Phase 2	Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab;Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab
38	Study to Evaluate Safety and Efficacy of Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine (DCX) in Patients With Gastro-esophageal Cancer	Unknown status	NCT00865982	Phase 2	Docetaxel, Cisplatin, Capecitabine
39	Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH	Unknown status	NCT01855854	Phase 2	Icotinib
40	Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma	Unknown status	NCT00964080	Phase 1, Phase 2	MBP-426/Leucovorin/5-FU
41	Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma	Completed	NCT00813072	Phase 2	PEP02;irinotecan;docetaxel
42	Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Completed	NCT00084604	Phase 2	irinotecan hydrochloride;cisplatin
43	Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma	Completed	NCT00183872	Phase 2	irinotecan, docetaxel
44	Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach	Completed	NCT01472029	Phase 2	5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab;Post-operative treatment trastuzumab mono therapy
45	Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment	Completed	NCT01262482	Phase 2	Oxaliplatin;Sorafenib
46	Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma	Completed	NCT00074009	Phase 2	bortezomib
47	Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma	Completed	NCT01932580	Phase 2	FLOT (5-fluorouracil, oxaliplatin, docetaxel)
48	Docetaxel+Oxali+/-Cetux Met Gastric/GEJ	Completed	NCT00517829	Phase 2	Docetaxel;cetuximab;oxaliplatin
49	Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer	Completed	NCT00737373	Phase 2	Docetaxel;5-Fluorouracil;Oxaliplatin;folinic acid
50	Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer	Completed	NCT01388790	Phase 2	Cetuximab;Cisplatin;S-1

Search NIH Clinical Center for Gastroesophageal Junction Adenocarcinoma

Sources

Genetic Tests for Gastroesophageal Junction Adenocarcinoma

Sources

Anatomical Context for Gastroesophageal Junction Adenocarcinoma

MalaCards organs/tissues related to Gastroesophageal Junction Adenocarcinoma:

⁴¹

Breast, Testes, Prostate, Endothelial, Lung, Bone, Lymph Node

Sources

Publications for Gastroesophageal Junction Adenocarcinoma

Articles related to Gastroesophageal Junction Adenocarcinoma:

(show top 50) (show all 78)

#	Title	Authors	Year
1	Perioperative chemotherapy vs. neoadjuvant chemoradiation inA gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry. ( 29071366 )	MA1nch S....Engel J.	2018
2	Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH. ( 29277796 )	Dominguez C....Coppola D.	2018
3	Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study. ( 29508095 )	Yamaguchi K....Satoh T.	2018
4	Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. ( 29094609 )	Joshi S.S....Catenacci D.V.	2018
5	Testicular Metastasis from Recurrent Gastroesophageal Junction Adenocarcinoma: Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Findings. ( 29430123 )	Garg I....Kendi A.T.	2018
6	Unusual case of left atrial myxoma with gastroesophageal junction adenocarcinoma. ( 29338297 )	Singh N.P....Dhingra B.K.	2018
7	Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. ( 29691300 )	Shah M.A....Bendell J.C.	2018
8	Combined taxane-based chemotherapy and intensity-modulated radiotherapy with simultaneous integrated boost for gastroesophageal junction adenocarcinoma. ( 29664354 )	Spatola C....Privitera G.	2018
9	Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. ( 29666803 )	Harada K....Ajani J.A.	2018
10	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. ( 29703766 )	Weinberg B.A....Marshall J.L.	2018
11	Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging. ( 28500616 )	Conway A.M....Mansoor W.	2017
12	Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma. ( 28524708 )	Papaxoinis G....Mansoor W.	2017
13	Health-related quality of life after gastrectomy, esophagectomy, and combined esophagogastrectomy for gastroesophageal junction adenocarcinoma. ( 28852939 )	Kauppila J.H....Lagergren P.	2017
14	HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. ( 28574779 )	Shah M.A....Tabernero J.	2017
15	Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India. ( 29199662 )	Babu K.G....Rajeev L.K.	2017
16	Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. ( 28424936 )	Anderegg M.C.J....van Hillegersberg R.	2017
17	External beam radiation and high-dose-rate brachytherapy for elderly patients with gastroesophageal junction adenocarcinoma. ( 28951752 )	Zhang W....Lang J.	2017
18	Clinical effectiveness and toxicity of second-line irinotecan in advanced gastric and gastroesophageal junction adenocarcinoma: a single-center observational study. ( 28491144 )	Ochenduszko S....BudzyA8ski A.	2017
19	HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma. ( 28588175 )	Rima F.A....Chowdhury F.	2017
20	Management and Reconstruction of a Gastroesophageal Junction Adenocarcinoma Patient Three Years after Pancreaticoduodenectomy: A Surgical Puzzle. ( 27635275 )	Dellaportas D....Davies A.R.	2016
21	Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. ( 26747859 )	Al-Batran S.E....Wilke H.	2016
22	No Survival Difference with Neaodjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base. ( 27641320 )	Al-Sukhni E....Hochwald S.N.	2016
23	Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. ( 27774774 )	Pericay C....Imedio E.R.	2016
24	Central nervous system relapse in patients with untreated her2-positive esophageal or gastroesophageal junction adenocarcinoma. ( 27198655 )	Yoon H.H....Sinicrope F.A.	2016
25	Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma. ( 27065846 )	Sigrand J....Raoul J.L.	2016
26	Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. ( 26354521 )	Ochenduszko S....Krzemieniecki K.	2015
27	Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma. ( 26625793 )	Madani S.H....Amirifard N.	2015
28	Comparisons of Clinical Outcomes and Prognoses in Patients With Gastroesophageal Junction Adenocarcinoma, by Transthoracic and Transabdominal Hiatal Approaches: A Teaching Hospital Retrospective Cohort Study. ( 26683954 )	Zhou J....Zhou Y.	2015
29	Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. ( 25753188 )	Blay C....Edeline J.	2015
30	Combined neutron brachytherapy with external beam radiation in patients with inoperable gastroesophageal junction adenocarcinoma. ( 25296599 )	Wang Q....Wan X.	2014
31	The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy. ( 24774780 )	Wang Q....Lang J.	2014
32	Personalizing risk stratification by addition of PAK1 expression to TNM staging: Improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma. ( 25159681 )	Li Z....Zhang H.	2014
33	Distant lymph node metastases in gastroesophageal junction adenocarcinoma: impact of endoscopic ultrasound-guided fine-needle aspiration. ( 24949383 )	Araujo J....Giovannini M.	2013
34	Meningeal carcinomatosis: a metastasis from gastroesophageal junction adenocarcinoma. ( 24454393 )	Dam T....Surani S.	2013
35	Prognostic importance and therapeutic implications of PAK1, a drugable protein kinase, in gastroesophageal junction adenocarcinoma. ( 24236193 )	Li Z....Zhang H.	2013
36	Results of docetaxel plus oxaliplatin (DOCOX) A+ cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. ( 23747051 )	Richards D....Asmar L.	2013
37	The metastasis-associated gene MTA3, a component of the Mi-2/NuRD transcriptional repression complex, predicts prognosis of gastroesophageal junction adenocarcinoma. ( 23671646 )	Dong H....Zhang H.	2013
38	The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel. ( 23420289 )	Bar-Sela G....Ben-Izhak O.	2013
39	Gastroesophageal junction adenocarcinoma metastasizing to gingiva. ( 23776844 )	Masamatti S.S....Sulhyan K.R.	2013
40	A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. ( 23921575 )	Park I....Kang Y.K.	2013
41	HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. ( 23656792 )	Shan L....Lu N.	2013
42	Reconstructive options for gastroesophageal junction adenocarcinoma after Roux-en-Y gastric bypass. ( 23988286 )	Kulaylat A.N....Kaifi J.T.	2013
43	Snail1 correlates with patient outcomes in E-cadherin-preserved gastroesophageal junction adenocarcinoma. ( 24356933 )	Dong H....Zhang H.	2013
44	Unanswered questions in the management of gastroesophageal junction adenocarcinoma. ( 23714486 )	Shah M.A.	2013
45	Relationship between gastroesophageal junction adenocarcinoma and Helicobacter pylori infection in Japan. ( 22472851 )	Kamada T....Haruma K.	2012
46	Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma. ( 21769462 )	Cohen D.J....Muggia F.	2012
47	HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. ( 22646280 )	Hechtman J.F....Polydorides A.D.	2012
48	HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. ( 21617522 )	Kunz P.L....Pai R.K.	2012
49	Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. ( 23412351 )	Jeromen A....RatoA!a I.	2012
50	Gastroesophageal junction adenocarcinoma of young patients who underwent curative surgery: a comparative analysis with older group. ( 21264755 )	Yoon H.Y....Kim C.B.	2011

Sources

Genes for Gastroesophageal Junction Adenocarcinoma

Genes related to Gastroesophageal Junction Adenocarcinoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	23.93	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	MTA3	Metastasis Associated 1 Family Member 3	Protein Coding	22.42	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	SNAI1	Snail Family Transcriptional Repressor 1	Protein Coding	20.46	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	IL1B	Interleukin 1 Beta	Protein Coding	17.03	GeneCards inferred via : Publications (show sections)
5	GUCY2C	Guanylate Cyclase 2C	Protein Coding	15.4	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)

Sources

Variations for Gastroesophageal Junction Adenocarcinoma

Sources

Expression for Gastroesophageal Junction Adenocarcinoma

Search GEO for disease gene expression data for Gastroesophageal Junction Adenocarcinoma.

Sources

Pathways for Gastroesophageal Junction Adenocarcinoma

Pathways related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	MAPK Pathway ⁷² Show member pathways Toll-like Receptor Pathway ⁷²	11.05	ERBB2 IL1B
2	Adherens junction ³⁷	10.48	ERBB2 SNAI1

Sources

GO Terms for Gastroesophageal Junction Adenocarcinoma

Biological processes related to Gastroesophageal Junction Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of protein phosphorylation	GO:0001934	9.16	ERBB2 IL1B
2	positive regulation of epithelial to mesenchymal transition	GO:0010718	8.96	IL1B SNAI1
3	regulation of ERK1 and ERK2 cascade	GO:0070372	8.62	ERBB2 IL1B

Sources

Sources for Gastroesophageal Junction Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia